Lixte Biotechnology Holdings, Inc. (LIXT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lixte Biotechnology Holdings, Inc. (LIXT) is up 70.7% since the beginning of the year. At $7 per share, LIXT is trading 10.5% below its 52-week high of $8. Investors who bought $1,000 worth of LIXT shares 5 years ago would now be looking at an investment worth $230.

Lixte Biotechnology Holdings, Inc. (LIXT) has returned 70.74% so far this year and 375.89% over the past 12 months. Over the last ten years, LIXT has returned -3.52% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Apr 8, 2010, LIXT's average daily return is +0.64%, while the average monthly return is +10.12%. At this rate, an investment would double in approximately 0.6 years.

Historically, 42% of months were positive and 58% were negative. The best month was Sep 2010 with a return of +950.0%, while the worst month was Aug 2010 at -82.9%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.

On a daily basis, LIXT closed higher 24% of trading days. The best single day was Sep 20, 2010 with a return of +950.0%, while the worst single day was Aug 19, 2010 at -70.0%.

Lixte Biotechnology Holdings, Inc. has an annualized alpha of 367.60%, beta of 0.55, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since April 09, 2010.

• This stock participated in 179.30% of S&P 500 Index downside but only 101.25% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.55 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LIXT ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Lixte Biotechnology Holdings, Inc. (LIXT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lixte Biotechnology Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lixte Biotechnology Holdings, Inc. was 99.12%, occurring on Jun 27, 2025. The portfolio has not yet recovered.

The current Lixte Biotechnology Holdings, Inc. drawdown is 91.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lixte Biotechnology Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lixte Biotechnology Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.